Tag: Dr Gisela Mautner
ASX biotech firm Noxopharm unveils anti-inflammatory skin disease drug
Australian biotech company Noxopharm Limited unveiled today its new preclinical product candidate from its Sofra technology platform that has shown effectiveness against inflammatory skin disease in preclinical models
Featured Article
From cost exposure to cost control: Using energy flexibility to protect margins
Electricity price volatility is reshaping the cost base of Australian manufacturing, challenging long-held assumptions that energy can be treated as a stable operational input.
